
SOTIO licences first cancer ADC from LegoChem Biosciences
The announcement of Czech immuno-oncology specialist SOTIO AS reported came along with promising safety and efficacy Phase I results of LegoChem...

Step Pharma presents promising cancer treatment
Since September 2022, STP938, the cancer inhibitor developed by Step Pharma SAS, has been undergoing clinical trials for the treatment of T and B...

Cradle BV bags €5.4m in seed financing
Cradle BV has raised $5.4m to push a machine-learning model-based platform that helps scientists to design and program cells much faster in order to...

Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

Growing investor interest in biotechnology
Institutional investors and financial analysts reported at the German Equity Forum that the biotech sector has become significantly more attractive....

Benefits of booster campaigns questionable
While Pfizer Inc and BioNTech SE financial outlooks in February prognosed more than $50bn in combined coronavirus disease (COVID-19) vaccine sales in...

Chong Kun Dang Pharm licences Synaffix ADC platform
Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...